Emerging Company Profile
Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology
Emerging Company Profile: dissecting normal and pathogenic biomolecular condensate biology to enable drug development
Third Rock’s Faze has launched with an $81 million series A to develop therapeutics targeting biomolecular condensates, starting with ALS and myotonic dystrophy type 1.
Dec 11, 2020 | 1:34 AM GMT
Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the
